Real-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study

Basit Öğe Kaydı
dc.contributor.authorSecilmis, Sema
dc.contributor.authorKabukcu Hacioglu, Sibel
dc.contributor.authorHindilerden, Fehmi
dc.contributor.authorTurgut, Burhan
dc.contributor.authorOzatli, Duzgun
dc.contributor.authorAkgun Cagliyan, Gulsum
dc.contributor.authorBasturk, Abdulkadir
dc.date.accessioned2026-04-04T13:31:02Z
dc.date.available2026-04-04T13:31:02Z
dc.date.issued2026
dc.departmentİnönü Üniversitesi
dc.description.abstractBackground/Objectives: Real-world data on the therapeutic use of FLT3 inhibitors in Turkey remain limited. Therefore, we retrospectively evaluated outcomes from 13 academic centers nationwide, focusing on the multikinase inhibitor midostaurin in patients with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). Methods: We collected comprehensive information regarding treatment efficacy, safety, and tolerability. Results: The overall response rate to intensive chemotherapy (3 + 7) plus midostaurin was 87.7%, with a complete remission rate of 84.2%, consistent with previously reported clinical trial results. Treatment discontinuation due to intolerance or toxicity was low (3.5%). One patient discontinued therapy because of septic shock during induction, and another due to a drug-drug interaction during consolidation. Median overall survival was 21.4 months. Allogeneic stem cell transplantation was performed in first remission in 52.6% of patients. Five patients (8.8%) were refractory to induction therapy, and relapse occurred in 21.1% (12 patients). Conclusions: These findings support the effectiveness and acceptable tolerability of midostaurin in routine clinical practice for FLT3-mutated AML.
dc.identifier.doi10.3390/jcm15020854
dc.identifier.issn2077-0383
dc.identifier.issue2
dc.identifier.orcid0000-0002-6297-9555
dc.identifier.orcid0000-0003-2868-665X
dc.identifier.pmid41598791
dc.identifier.scopus2-s2.0-105028763604
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.3390/jcm15020854
dc.identifier.urihttps://hdl.handle.net/11616/108543
dc.identifier.volume15
dc.identifier.wosWOS:001670722700001
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherMdpi
dc.relation.ispartofJournal of Clinical Medicine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WOS_20250329
dc.subjectacute myeloid leukemia
dc.subjectAML
dc.subjectFLT3 inhibitors
dc.subjectmidostaurin
dc.titleReal-World Utilization of Midostaurin in Combination with Intensive Chemotherapy for Patients with FLT3 Mutated Acute Myeloid Leukemia: A Multicenter Study
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu